Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens

被引:0
|
作者
Sumana Srivatsa
Hesam Montazeri
Gaia Bianco
Mairene Coto-Llerena
Mattia Marinucci
Charlotte K. Y. Ng
Salvatore Piscuoglio
Niko Beerenwinkel
机构
[1] ETH Zurich,Department of Biosystems Science and Engineering
[2] SIB Swiss Institute of Bioinformatics,Department of Bioinformatics, Institute of Biochemistry and Biophysics
[3] University of Tehran,Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine
[4] University of Basel,Institute of Medical Genetics and Pathology
[5] University Hospital Basel,Department for BioMedical Research
[6] University of Bern,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The development of cancer therapies is limited by the availability of suitable drug targets. Potential candidate drug targets can be identified based on the concept of synthetic lethality (SL), which refers to pairs of genes for which an aberration in either gene alone is non-lethal, but co-occurrence of the aberrations is lethal to the cell. Here, we present SLIdR (Synthetic Lethal Identification in R), a statistical framework for identifying SL pairs from large-scale perturbation screens. SLIdR successfully predicts SL pairs even with small sample sizes while minimizing the number of false positive targets. We apply SLIdR to Project DRIVE data and find both established and potential pan-cancer and cancer type-specific SL pairs consistent with findings from literature and drug response screening data. We experimentally validate two predicted SL interactions (ARID1A-TEAD1 and AXIN1-URI1) in hepatocellular carcinoma, thus corroborating the ability of SLIdR to identify potential drug targets.
引用
收藏
相关论文
共 50 条
  • [1] Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens
    Srivatsa, Sumana
    Montazeri, Hesam
    Bianco, Gaia
    Coto-Llerena, Mairene
    Marinucci, Mattia
    Ng, Charlotte K. Y.
    Piscuoglio, Salvatore
    Beerenwinkel, Niko
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [2] Large-scale compound screens and pharmacogenomic interactions in cancer
    McDermott, Ultan
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2019, 54 : 12 - 16
  • [3] Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens
    Karimpour, Mina
    Totonchi, Mehdi
    Behmanesh, Mehrdad
    Montazeri, Hesam
    [J]. LIFE SCIENCE ALLIANCE, 2024, 7 (01)
  • [4] A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens
    Price, Stacey
    Bhosle, Shriram
    Goncalves, Emanuel
    Li, Xiaodun
    McClurg, Dylan P.
    Barthorpe, Syd
    Beck, Alex
    Hall, Caitlin
    Lightfoot, Howard
    Farrow, Luke
    Ansari, Rizwan
    Jackson, David A.
    Allen, Laura
    Roberts, Kirsty
    Beaver, Charlotte
    Francies, Hayley E.
    Garnett, Mathew J.
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [5] A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens
    Stacey Price
    Shriram Bhosle
    Emanuel Gonçalves
    Xiaodun Li
    Dylan P. McClurg
    Syd Barthorpe
    Alex Beck
    Caitlin Hall
    Howard Lightfoot
    Luke Farrow
    Rizwan Ansari
    David A. Jackson
    Laura Allen
    Kirsty Roberts
    Charlotte Beaver
    Hayley E. Francies
    Mathew J. Garnett
    [J]. Scientific Reports, 12
  • [6] Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis
    Guo, Li
    Li, Sunjing
    Qian, Bowen
    Wang, Youquan
    Duan, Rui
    Jiang, Wenwen
    Kang, Yihao
    Dou, Yuyang
    Yang, Guowei
    Shen, Lulu
    Wang, Jun
    Liang, Tingming
    [J]. COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2020, 18 (18): : 3243 - 3254
  • [7] Large-scale screens for cancer genes in the mouse
    van der Weyden, Louise
    Rust, Alistair
    Perez-Mancera, Pedro
    Tuveson, David
    Jonkers, Jos
    Mullighan, Charles
    Winton, Doug
    Adams, David
    [J]. CANCER RESEARCH, 2012, 72
  • [8] Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
    Bashi, Azadeh C.
    Coker, Elizabeth A.
    Bulusu, Krishna C.
    Jaaks, Patricia
    Crafter, Claire
    Lightfoot, Howard
    Milo, Marta
    McCarten, Katrina
    Jenkins, David F.
    van der Meer, Dieudonne
    Lynch, James T.
    Barthorpe, Syd
    Andersen, Courtney L.
    Barry, Simon T.
    Beck, Alexandra
    Cidado, Justin
    Gordon, Jacob A.
    Hall, Caitlin
    Hall, James
    Mali, Iman
    Mironenko, Tatiana
    Mongeon, Kevin
    Morris, James
    Richardson, Laura
    Smith, Paul D.
    Tavana, Omid
    Tolley, Charlotte
    Thomas, Frances
    Willis, Brandon S.
    Yang, Wanjuan
    O'Connor, Mark J.
    McDermott, Ultan
    Critchlow, Susan E.
    Drew, Lisa
    Fawell, Stephen E.
    Mettetal, Jerome T.
    Garnett, Mathew J.
    [J]. CANCER DISCOVERY, 2024, 14 (05) : 846 - 865
  • [9] Prognostic evaluation of polygenic risk score underlying pan-cancer analysis: evidence from two large-scale cohorts
    Xin, Junyi
    Jiang, Xia
    Li, Huiqin
    Chen, Silu
    Zhang, Zhengdong
    Wang, Meilin
    Gu, Dongying
    Du, Mulong
    Christiani, David C.
    [J]. EBIOMEDICINE, 2023, 89
  • [10] Identification of Potential Biomarkers for Pan-Cancer Diagnosis and Prognosis Through the Integration of Large-Scale Transcriptomic Data
    Zhu, Lin
    Miao, Yu
    Xi, Feng
    Jiang, Pingping
    Xiao, Liang
    Jin, Xin
    Fang, Mingyan
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13